Neogenomics (NEO) Stock
Specialized cancer testing firm with national laboratory network. Here's the price, business snapshot, and what's worth knowing about Neogenomics in October 2026.
NeoGenomics, Inc. (NEO) is a US-based specialised diagnostics company focused on cancer testing and pathology services. It operates a network of clinical laboratories that offer genetic sequencing, blood-based assays and advanced tumour profiling to oncologists, hospitals and biopharma clients. Revenue growth has been driven by rising demand for precision oncology tests, expanding test menus and strategic acquisitions that broaden geographic reach and capabilities. Investors should note the company’s exposure to reimbursement rates, lab utilisation and regulatory oversight — which can affect margins and volume. With a market capitalisation around $1.35 billion, NeoGenomics sits in the small‑cap / mid‑cap range and can show higher volatility than large diversified peers. The business can benefit from secular growth in personalised medicine, but outcomes depend on execution, pricing pressure and test adoption. This summary is for general educational purposes and not personalised investment advice; returns are not guaranteed and values can fall as well as rise.
Neogenomics (NEO) Stock Forecast
Analyst price target, next 12 months
$20.31
+9.9% vs today's $18.47
Price range over the last 12 months
Close to its 12-month high
Analysts covering Neogenomics have a consensus 12-month target of $20.31, above the current price of $18.47.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying NEOGENOMICS stock, believing it may reach a higher price soon.
Financial Health
Neogenomics has steady revenue and cash flow, but its profits are relatively low compared to sales.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Tumour Profiling Growth
Rising demand for personalised oncology tests supports revenue expansion, though adoption rates and pricing can vary by region and payer.
Lab Network Expansion
Acquisitions and capacity investments can drive scale and service breadth, but integration and execution risks may affect near‑term margins.
Reimbursement Sensitivity
Revenue is sensitive to reimbursement policies and insurer decisions; favourable coverage boosts volumes, while cuts can pressure earnings.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
